Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Alzheimer Disease Clinical Trial

Official title:

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04080544
• Other study ID #: STU 092015-003
• Status: Completed
• Phase: Phase 2
• Start date: January 15, 2019
• Est. completion date: June 30, 2022

Study information

• Verified date: August 2023
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 ([18F]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.

Description:

Alzheimer's disease (AD) is a highly prevalent disorder of dementia in older adults. AD neuropathology is marked by the presence of amyloid plaques and tau neurofibrillary tangles. Autopsy studies, as well as magnetic resonance imaging (MRI) studies in living persons, have established that the neurodegenerative changes in AD begin in medial temporal lobe structures and later progress to adjacent temporal, parietal and frontal neocortical regions. Magnetic resonance image studies of AD consistently reveal volumetric loss in the hippocampus using both cross-sectional and longitudinal approaches. The primary symptom of early-stage AD is memory impairment possibly accompanied by deficits in attentional control. Normal aging, however, is also marked by cognitive decline, as well as structural brain changes. Autopsy data had shown in the past that about 30% of older adults with no obvious cognitive impairment show some degree of the neuropathology typically associated with dementia at autopsy.

Importantly, the recent ability to image beta-amyloid and tau deposits in vivo using positron emission tomography (PET) scanning has revolutionized our understanding of early stages of AD. Evidence suggests that amyloid deposits may be detected 10 - 15 years before memory symptoms appear. These findings are leading to the ability to diagnose AD years before symptoms begin. Much less is known about the impact and developmental course of tau deposition as compared to beta-amyloid because the ligand to image tau was only recently invented. There is increasing evidence that tau is particularly toxic to the brain and is a later precursor of AD than amyloid deposits. Additional research on beta-amyloid and tau deposition in aging is crucial, as much work suggests that treatment of AD may be most effective when implemented early in the time course of the disease. Understanding the impact of tau deposits and its interactions with amyloid deposition allows the investigators to see the development of early markers of AD, which are important in understanding the trajectory of the disease. An important approach to understand the amyloid/tau puzzle and its relationship to AD is a large-scale longitudinal study of normal aging that integrates extensive neuroimaging and cognitive assessments along with tau imaging. A key aspect in understanding pathological aging is the need to be able to clearly differentiate normal aging from early pathology. The present Tau imaging study described here is an important component of the Dallas Lifetime Brain Study (DLBS).

The Dallas Lifespan Brain Study (DLBS) began in 2008 and was designed to utilize the new in vivo imaging techniques to address uncertainty regarding how AD pathology relates to the developmental process of aging and cognition, fueled in part by the partial overlap of pathological markers and decline in mnemonic function observed in a substantial proportion of 'normal' aged individuals. A total of 296 participants were recruited for Wave 1 from 2008 to 2014 to the DLBS and they received cognitive testing, structural and functional MRI, as well as a scan for beta amyloid using the radioligand AV-45 Florbetapir F 18 (also known as "[18F]AV-45"). A total of 183 returning participants were tested four years later in Wave 2, and they received the same battery as in Wave 1. In addition, 60 of these were also scanned with Flortaucipir F 18 (also known as "[18F]AV-1451"). [18F]AV-1451 is a newly-developed Phase II ligand that measures tau deposit in the human brain and this drug was provided to the DLBS by Avid Radiopharmaceuticals.

The objective of the current study is to test 125 DLBS participants with [18F]AV-1451 (Flortaucipir F 18) at the University of Texas Southwestern Medical Center (UTSW). The inclusion of tau imaging in Wave 3 will allow the investigators to relate tau deposition in the brain to the 10-year history of amyloid deposition and cognitive decline in the DLBS participants and understand the independent and joint contributions of tau to cognitive decline and early AD at different ages.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 125
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 38 Years to 96 Years

Eligibility

Inclusion Criteria:

• Participated in Wave 1 or 2 of the DLBS study.

• Subjects must indicate that they are not currently pregnant if they are women of child-bearing potential. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1) Has not undergone a hysterectomy or bilateral oophorectomy; or 2) Has not been naturally post-menopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

• Volumetric Brain MRI Image (T-1 Weighted MPRage) collected as part of DLBS Wave 1, 2, or 3 protocol.

• Completed at least 9 years of formal education, or the equivalent of freshman year of high school.

• Fluent English speakers.

• Tolerate laying 20 minutes on a flat table for the PET scan.

• Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• Mini-Mental State Examination (MMSE) score lower than 22; all DLBS participants at the time of initial Wave 1 enrollment between 2008 - 2014 had an MMSE score of 26 or above, indicating normal cognitive function. However, in the time interval between Wave 1 and Wave 3, it is possible that mental capacity may have deteriorated. The investigators will exclude all participants in Wave 3 testing who have an MMSE lower than 22.

• Taking some types of sedatives, benzodiazepines, or anti-psychotics.

• Currently undergoing chemotherapy or radiation for cancer.

• New history of substance abuse.

• Has a history of drug or alcohol dependence within the last year, or prior prolonged history of dependence.

• Recreational drug use in past six months.

• Central nervous systems disease or brain injury that would preclude participation in the study.

• Psychiatric or neurological disorder that would preclude participation in this study.

• Has clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances which pose safety risk.

• Has a current clinically significant cardiovascular disease that poses a safety risk.

• Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk.

• Has either: 1) Screening electrocardiogram (ECG) with corrected QT Interval (QTc) > 450 millisecond (msec) if male, or QTc > 470 msec if female; or 2) A history of additional risk factors for Torsades de Pointes (TdP) (e.g., hypokalemia, family history of Long QT syndrome) or are taking drugs that are known to cause QT prolongation (a list of prohibited and discouraged medications is provided by the Sponsor); Patients with a prolonged QTc interval in the setting of intraventricular conduction block (examples right bundle branch block or left bundle branch block), may be enrolled with sponsor approval.

• Has received or will receive investigational medication within the 30 days of PET/CT scan.

• Has received or will receive a radiopharmaceutical for imaging or therapy within 24 hours of PET/CT scan.

• Is a participant who, in the opinion of the investigator(s), is otherwise unsuitable for a study of this type.

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Decline
• Cognitive Dysfunction

Intervention

Drug:
• [18F]AV-1451
The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of [18F]AV-1451.

Procedure:
• Positron Emission Tomography
Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.

Locations

Country	Name	City	State
United States	UT Southwestern Medical Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Neil M Rofsky, MD, MHA

Country where clinical trial is conducted

United States, 

References & Publications (18)

Balota D.A., Faust M.E. (2001). Attention in dementia of the Alzheimer's type. In: Boller F, Cappa S, editors. Handbook of Neuropsychology. 2nd Ed. NY: Elsevier Science; pp. 51-80.

Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006 May;5(5):406-12. doi: 10.1016/S1474-4422(06)70417-3. — View Citation

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59. doi: 10.1007/BF00308809. — View Citation

Convit A, de Leon MJ, Golomb J, George AE, Tarshish CY, Bobinski M, Tsui W, De Santi S, Wegiel J, Wisniewski H. Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatr Q. 1993 Winter;64(4):371-87. doi: 10.1007/BF01064929. — View Citation

Holm S: A Simple Sequentially Rejective Bonferroni Test. Scandinavian Journal of Statistics. 1979, 65 -670.

Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997 Sep;49(3):786-94. doi: 10.1212/wnl.49.3.786. — View Citation

Jack, C., Knopman, D., Jagust, W., Petersen, R., Weiner, M., Aisen, P., … Trojanowski, J. (2013). Update on hypothetical model of Alzheimer's disease biomarkers. Alzheimer's & Dementia, 9(4), 521-522.

Kemper S, Anagnopoulos C, Lyons K, Heberlein W. Speech accommodations to dementia. J Gerontol. 1994 Sep;49(5):P223-9. doi: 10.1093/geronj/49.5.p223. — View Citation

Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097-105. doi: 10.1001/archneur.1985.04060100083029. No abstract available. — View Citation

Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol. 1993 Sep;50(9):949-54. doi: 10.1001/archneur.1993.00540090052010. — View Citation

Mohs RC, Ashman TA, Jantzen K, Albert M, Brandt J, Gordon B, Rasmusson X, Grossman M, Jacobs D, Stern Y. A study of the efficacy of a comprehensive memory enhancement program in healthy elderly persons. Psychiatry Res. 1998 Feb 27;77(3):183-95. doi: 10.1016/s0165-1781(98)00003-1. — View Citation

Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol. 2009;60:173-96. doi: 10.1146/annurev.psych.59.103006.093656. — View Citation

Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001 Sep;58(9):1395-402. doi: 10.1001/archneur.58.9.1395. — View Citation

Reuter-Lorenz PA, Park DC. How does it STAC up? Revisiting the scaffolding theory of aging and cognition. Neuropsychol Rev. 2014 Sep;24(3):355-70. doi: 10.1007/s11065-014-9270-9. Epub 2014 Aug 21. — View Citation

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21. — View Citation

Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002 Oct 8;59(7):1034-41. doi: 10.1212/wnl.59.7.1034. — View Citation

Trojanowski JQ, Clark CM, Schmidt ML, Arnold SE, Lee VM. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S75-9. doi: 10.1016/s0197-4580(97)00075-4. — View Citation

Whalley LJ. Brain ageing and dementia: what makes the difference? Br J Psychiatry. 2002 Nov;181:369-71. doi: 10.1192/bjp.181.5.369. No abstract available. — View Citation

* Note: There are 18 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans	Tau accumulation in the temporal lobe will be measured as the standardized uptake value ratio (SUVR) computed from each participant's [18F]AV-1451 PET scans averaged across six bilateral regions of interest (ROls) by normalizing regional counts to the whole cerebellum. The 6 ROls are: inferior temporal gyrus, middle temporal gyrus, superior temporal gyrus, entorhinal cortex, parahippocampal gyrus, and fusiform gyrus. Each participant's PET scan and the six bilateral ROIs will be coregistered to their T1-weighted MRI (MP-RAGE). Finally, the mean observed tracer count from each region will be extracted and normalized using whole cerebellum as the reference. Observed tau SUVR scores in humans range from 0.5 to 2.5, with higher scores being indicative of greater tau accumulation. Unless otherwise specified, all subsequent analyses will use this temporal tau SUVR and will involve examination of cross-sectional relationships between tau SUVR and key outcome measures at Wave 3 of the DLBS.	An average of 3-months post-PET study visit
Secondary	Relationship of Tau Burden to Episodic Memory Function	Episodic memory is a construct that measures how well individuals can store, maintain, and retrieve detailed information in long-term memory. Episodic memory will be a composite score using the Hopkins Verbal Learning test with 3 subcomponents (immediate recall: range 0-12, delayed recall: range 0-12, and recognition: range 0-24) and the immediate recall of the CANTAB Verbal Recognition Memory task (range 0-12). Scores from the tasks will be converted to Z-scores and averaged to form an episodic memory composite, and then this final value with be converted to a Z-score. A higher composite Z-score indicates better episodic memory, a Z-score of 0 represents the population mean, and all Z-scores have a standard deviation of 1. Values in this table represent this Episodic Memory Z-score.	1-year post study completion
Secondary	Relationship of Amyloid Accumulation to Tau Burden	Amyloid accumulation throughout the Dallas Lifespan Brain Study (6-9.8 years) will be measured with Florbetapir F18 and calculated as an Amyloid Standard Uptake Value ratio (SUVR) by normalizing regional counts to the whole cerebellum. Amyloid SUVR scores will be averaged across eight cortical regions spanning most of the cortex: dorsal lateral prefrontal cortex, orbitofrontal cortex, lateral parietal cortex, posterior cingulate cortex, anterior cingulate cortex, precuneus, lateral temporal cortex, and lateral occipital lobe. Amyloid SUVR scores observed in this study have ranged from 0.88 to 1.74, with higher scores being indicative of greater amyloid accumulation. Finally, annualized change scores for these amyloid SUVRs across the full study duration (6-9.8 years) will be calculated to determine the extent that the rate of amyloid accumulation relates to tau burden at the end of the study.	1-year post study completion
Secondary	Relationship of Tau Burden to Speed of Processing	Speed of processing is a construct that measures how rapidly individuals can process information. To assess speed of processing, a composite score will be created using the Digit Comparison task and the Wechsler Adult Intelligence Scale (WAIS) Digit Symbol task. Observed DLBS raw scores range from 27 to 116 for Digit Comparison task and 20 to 90 for Digit Symbol task. Participants' raw scores are converted to Z-scores and averaged to form a speed of processing composite, and then this final value with be converted to a Z-score. A higher composite Z-score indicates better speed of processing, a Z-score of 0 represents the population mean, and all Z-scores have a standard deviation of 1. Values in this table represent this Speed of Processing Z-score.	1-year post study completion
Secondary	Relationship of Tau Burden to Reasoning	The construct of reasoning measures an individual's ability to recognize novel patterns and the conceptual relationship among objects and effectively apply these patterns to solve similar problems. To assess reasoning, a composite score will be created using the Raven's Progressive Matrices task and Educational Testing Service (ETS) Letters Sets task. Observed DLBS raw scores range from 9 to 30 for Raven's Progressive Matrices task and from 0.5 to 30 for ETS Letters Sets task. Raven's Progress Matrices and ETS Letter Sets will be converted to Z-scores and averaged to form a reasoning composite, and then this final value with be converted to a Z-score. A higher composite Z-score indicates higher reasoning ability, a Z-score of 0 represents the population mean, and all Z-scores have a standard deviation of 1. Values in this table represent this Reasoning Z-score.	1-year post study completion
Secondary	Relationship of Tau Burden to Working Memory	Working memory is a construct that measures the ability of individuals to simultaneously manipulate and store information. To assess working memory, a composite score will be created using the CANTAB Spatial Working Memory task (reverse scored) and the Wechsler Adult Intelligence Scale (WAIS-III) Letter Number Sequencing task. Observed DLBS raw scores range from 0 to 86 total errors for the CANTAB Spatial Working Memory task and 2 to 20 for the WAIS-III Letter Number Sequencing task. Participants' raw scores are converted to Z-scores and averaged to form a working memory composite, and then this final value with be converted to a Z-score. A higher working memory composite Z-score indicates better working memory, a Z-score of 0 represents the population mean, and all Z-scores have a standard deviation of 1. Values in this table represent this Working Memory Z-score.	1-year post study completion
Secondary	Relationship of Tau Burden to Participants' Age	Linear regressions between the AV-1451 SUVR in each of the temporal regions of interest with participant age will be calculated, and in additional analyses, non-linear effects of age will be examined via quadratic and growth modeling. Observed AV-1451 SUVR scores in humans have ranged from 0.5 to 2.5, with higher scores being indicative of greater tau accumulation. The investigators predict that tau accumulation will accelerate in old age, thus supporting a non-linear rate of deposition.	1-year post study completion
Secondary	Relationship of Tau Burden to Cortical Thickness	Regional cortical thickness will be estimated from previously acquired T1-weighted structural magnetic resonance imaging (MRl) scans using FreeSurfer (ver. 5.3), with surface parcellation manually edited when necessary by our team of experts. The regions selected for analyses of cortical thickness were the ROIs used to estimate temporal tau SUVR: inferior temporal gyrus, middle temporal gyrus, superior temporal gyrus, entorhinal cortex, parahippocampal gyrus, and fusiform gyrus. Observed cortical thickness in these regions range from 1.38 to 3.83 mm with higher scores indicating greater thickness.	1-year post study completion
Secondary	Relationship of Tau Burden to Hippocampal Volume	Hippocampal volume will be estimated from previously acquired T1-weighted structural magnetic resonance imaging (MRl) scans using FreeSurfer (ver. 5.3), with surface parcellation manually edited when necessary by our team of experts. This region was selected for analysis as it was one of the ROIs used to estimate temporal tau SUVR. Observed DLBS hippocampal volume ranged from 1843 to 5342 mm^3 with higher scores indicating greater volume.	1-year post study completion
Secondary	Relationship of Tau Burden to White Matter Integrity	White matter integrity will be assessed using the estimated volume of white matter hypointensities from previously acquired T1-weighted structural magnetic resonance imaging (MRl) scans using FreeSurfer (ver. 5.3). Observed DLBS white matter hypointensities range from 796 to 35,037 mm^3 with higher scores indicating greater volume of hypointensities and reflecting worse white matter integrity.	1-year post study completion
Secondary	Relationship of Tau Burden to Functional Magnetic Resonance Imaging (MRI)	For functional measures, blood oxygenation level dependent signal from contrasts of interest using selected ROls will be created. For the semantic judgment task (easy judgments - fixation), the investigators will focus on ROIs associated with processing meaning, including inferior frontal gyrus, precuneus, and middle temporal gyrus. Observed BOLD activation values (betas) ranged from -1.00 to 1.30 with higher values indicating greater activation.	1-year post study completion
Secondary	Relationship of Tau Burden to Resting-State Brain System Segregation	Resting-state brain system segregation was computed on data collected from a separate resting-state scan using graph theory. System segregation is calculated as (Zw - Zb) / Zw, where Zw is the mean Fisher z-transformed r between nodes with the same system and Zb is the mean Fisher z-transformed r between nodes of one system to all nodes in other systems. Higher values indicate reduced node-node connectivity between systems relative to within-system connectivity. A score of 0 would reflect equal resting-state connectivity between nodes within the same functional system and between nodes of separate systems. Like all Z-scores, these scores typically range from -3 to 3. Higher scores are observed in younger adults than in older adults and may suggest a more youth-like brain, though higher scores are not objectively better. Systems were defined based on Power et al., (2011, Neuron) and more details on this measure are described in Chan et al. (2014, PNAS).	1-year post study completion